Universe Pharmaceuticals INC (NASDAQ:UPC – Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 30th, there was short interest totaling 43,865 shares, a decline of 42.2% from the September 15th total of 75,844 shares. Currently, 2.0% of the company’s shares are short sold. Based on an average daily volume of 40,506 shares, the short-interest ratio is currently 1.1 days.
Wall Street Analyst Weigh In
UPC has been the subject of a number of research analyst reports. Weiss Ratings raised Universe Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. Wall Street Zen raised Universe Pharmaceuticals to a “hold” rating in a research report on Saturday, August 29th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.
Read Our Latest Research Report on Universe Pharmaceuticals
Universe Pharmaceuticals Stock Performance
Universe Pharmaceuticals (NASDAQ:UPC – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($1.38) EPS for the quarter. The firm had revenue of $4.52 million during the quarter.
About Universe Pharmaceuticals
Universe Pharmaceuticals Inc (NASDAQ: UPC) is a China-based pharmaceutical company engaged in the development, manufacture and sale of traditional Chinese medicine (TCM) products and other healthcare offerings. The company serves consumers primarily through pharmaceutical distributors, retail pharmacies and other sales channels in China.
Universe Pharmaceuticals’ product portfolio includes over-the-counter and prescription pharmaceutical products, as well as healthcare and nutritional products.
Further Reading
- Five stocks we like better than Universe Pharmaceuticals
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
- Fastenal Flashes Bullish Signal as Uptrend Holds Despite Margin Pressure
Receive News & Ratings for Universe Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Universe Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
